Project Grant K22AI179939
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$162K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
The Washington University in St. Louis has been awarded a $140,256 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to discover how the tuberculosis-causing bacterium Mycobacterium tuberculosis (MTB) promotes its survival within neutrophils, the most abundant immune cells at sites of TB infection. Specifically, the research aims to elucidate the role of the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute. The grant, titled "Mechanisms of Efficient Control of Mycobacterium Tuberculosis in the Lungs Prior to Granuloma," aims to develop novel vaccination strategies to contain the tuberculosis pandemic. The research will use cutting-edge techniques like single-cell RNA...
The Washington University in St. Louis was awarded a $772,420 Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to conduct research on understanding early interactions between macrophages and T cells, and the role of the SLAMF1 receptor in immunity to tuberculosis (TB). The research aims to elucidate the mechanisms by which CD4 T cells confer protection against Mycobacterium tuberculosis (MTB) infection, focusing...
This federal Project Grant award of $769,925.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the role of lung alveolar macrophage (AM) ontogeny and metabolism in regulating the permissiveness of AMs to Mycobacterium tuberculosis (MTB) infection. The research will utilize immunology, metabolism, genomics, microbiology, novel mouse models, and human primary AMs to understand how...
This federal Project Grant award of $320,788 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to better understand the role of antigen-independent T cell activation, also known as "bystander activation," in controlling Mycobacterium tuberculosis (M.tb) infection. Specifically, the research aims to determine the ability of CD1a/b/c-restricted T cells to undergo bystander...
This $3,559,162 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to modulate indoleamines and optimize immunity in the setting of Mycobacterium tuberculosis (MTB)/HIV co-infection. The project, which runs from June 2024 to April 2029, aims to use macaque models of MTB/SIV co-infection to study the role of the IDO pathway in inhibiting effective immunity to TB and...
This federal Project Grant award of $447,009 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) categorize AM sensing abilities and defects using ex vivo and in vivo delivery of MTB-related pathogen associated molecular patterns (PAMPs),...
This federal Project Grant award, valued at $899,894 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research on understanding the interactions between macrophages, neutrophils, and HIV that contribute to tuberculosis (TB) disease progression. The key products and services to be delivered under this grant include: Defining the type I interferon (IFN) signaling and...
This $246,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The key objectives are to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in controlling Mycobacterium tuberculosis (MTB) infection and preventing TB reactivation, as well...
This $820,246 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at the Albert Einstein College of Medicine to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The grant aims to determine how these secreted proteins contribute to TB disease...